{"id":"NCT00723606","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","officialTitle":"A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2008-07-29","resultsPosted":"2010-08-25","lastUpdate":"2021-03-03"},"enrollment":376,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Intramuscular ziprasidone mesylate","otherNames":["Zeldox, Geodon"]},{"type":"DRUG","name":"Intramuscular haloperidol","otherNames":["Haldol"]}],"arms":[{"label":"Intramuscular ziprasidone","type":"EXPERIMENTAL"},{"label":"Intramuscular haloperidol","type":"ACTIVE_COMPARATOR"}],"summary":"This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia","primaryOutcome":{"measure":"Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours","timeFrame":"Baseline, 72 hours","effectByArm":[{"arm":"Ziprasidone","deltaMin":-17.32,"sd":0.692},{"arm":"Haloperidol","deltaMin":-18.44,"sd":0.72}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":9,"countries":["China"]},"refs":{"pmids":["23422376"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281152&StudyName=A%20Randomized%2C%20Open-Label%2C%20Multi-Center%20Study%20To%20Evaluate%20The%20Efficacy%20And%20Safety%20Of%20Intramuscular%20Ziprasidone%20In%20Patients%20With%20Agitation"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":189},"commonTop":["Extrapyramidal disorder","Somnolence","Akathisia","Dizziness","Insomnia"]}}